Acetylcholine Suppresses LPS-induced Endothelial Cell Activation by Inhibiting the MAPK and NF-κB Pathways.
Ping Li,Kewen Zhou,Jiehao Li,Xiaodan Xu,Ling Wang,Tinghuai Wang
DOI: https://doi.org/10.1684/ecn.2023.0481
2022-01-01
European Cytokine Network
Abstract:Endothelial cell activation plays a critical role in leukocyte recruitment during inflammation and infection. We previously found that cholinergic stimulation (via vagus nerve stimulation) attenuates vascular endothelial impairment and reduces the inflammatory profile in ovariectomized rats. However, the specific molecular mechanism is unclear. This study was designed to explore the effects and molecular mechanisms of cholinergic agonists (acetylcholine [ACh]) on lipopolysaccharide (LPS)-induced endothelial cell activation in vitro. Human umbilical vein endothelial cells (HUVECs) were treated with different concentrations of LPS (10/100/1000 ng/mL) to activate endothelial cells. HUVECs were untreated, treated with ACh (10−5 M) alone, treated with 100 ng/mL LPS alone, or treated with different concentrations of ACh (10−9/10−8/10−7/10−6/10−5 M) before LPS stimulation. HUVECs were also pre-treated with 10−6 M ACh with or without mecamylamine (an nAChR blocker) (10 µM) and methyllycaconitine (a specific α7 nAChR blocker) (10 µM) and incubated with or without LPS. ELISA, western blotting, cell immunofluorescence, and cell adhesion assays were used to examine inflammatory cytokine production, adhesion molecule expression, monocyte-endothelial cell adhesion and activation of the MAPK/NF-κB pathways. LPS (at 10 ng/mL, 100 ng/mL and 1,000 ng/mL) increased VCAM-1 expression in HUVECs in a dose-dependent manner (with no significant difference between LPS at 100 ng/mL and 1,000 ng/mL). ACh (10−9 M–10−5 M) blocked adhesion molecule expression (VCAM-1, ICAM-1, and E-selectin) and inflammatory cytokine production (TNF-α, IL-6, MCP-1, IL-8) in response to LPS in a dose-dependent manner (with no significant difference between 10−5 and 10−6 M Ach). LPS was also shown to significantly enhance monocyte-endothelial cell adhesion, which was largely abrogated by treatment with ACh (10−6 M). VCAM-1 expression was blocked by mecamylamine rather than methyllycaconitine. Lastly, ACh (10−6 M) significantly reduced LPS-induced phosphorylation of NF-κB/p65, IκBα, ERK, JNK and p38 MAPK in HUVECs, which was blocked by mecamylamine. ACh protects against LPS-induced endothelial cell activation by inhibiting the MAPK and NF-κB pathways, which are mediated by nAChR, rather than α7 nAChR. Our results may provide novel insight into the anti-inflammatory effects and mechanisms of ACh.